Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Treasury Shares: 2023-2025

Historic Treasury Shares for Avidity Biosciences (RNA) over the last 2 years, with Mar 2025 value amounting to $2.6 million.

  • Avidity Biosciences' Treasury Shares rose 85.87% to $2.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.6 million, marking a year-over-year increase of 85.87%. This contributed to the annual value of $2.1 million for FY2024, which is 178.50% up from last year.
  • Latest data reveals that Avidity Biosciences reported Treasury Shares of $2.6 million as of Q1 2025, which was up 24.59% from $2.1 million recorded in Q4 2024.
  • In the past 5 years, Avidity Biosciences' Treasury Shares ranged from a high of $2.6 million in Q1 2025 and a low of $607,000 during Q1 2023.
  • In the last 3 years, Avidity Biosciences' Treasury Shares had a median value of $1.4 million in 2024 and averaged $1.3 million.
  • Data for Avidity Biosciences' Treasury Shares shows a peak YoY skyrocketed of 178.50% (in 2024) over the last 5 years.
  • Avidity Biosciences' Treasury Shares (Quarterly) stood at $758,000 in 2023, then skyrocketed by 178.50% to $2.1 million in 2024, then soared by 85.87% to $2.6 million in 2025.
  • Its Treasury Shares stands at $2.6 million for Q1 2025, versus $2.1 million for Q4 2024 and $1.6 million for Q3 2024.